A Molecular Stratification of Chilean Gastric Cancer Patients with Potential Clinical Applicability.

Published on Jul 10, 2020in Cancers6.126
· DOI :10.3390/CANCERS12071863
Mauricio P. Pinto11
Estimated H-index: 11
(UC: Pontifical Catholic University of Chile),
Miguel Cordova-Delgado6
Estimated H-index: 6
(UC: Pontifical Catholic University of Chile)
+ 15 AuthorsMarcelo Garrido21
Estimated H-index: 21
(UC: Pontifical Catholic University of Chile)
Gastric cancer (GC) is a complex and heterogeneous disease. In recent decades, The Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) defined GC molecular subtypes. Unfortunately, these systems require high-cost and complex techniques and consequently their impact in the clinic has remained limited. Additionally, most of these studies are based on European, Asian, or North American GC cohorts. Herein, we report a molecular classification of Chilean GC patients into five subtypes, based on immunohistochemical (IHC) and in situ hybridization (ISH) methods. These were Epstein–Barr virus positive (EBV+), mismatch repair-deficient (MMR-D), epithelial to mesenchymal transition (EMT)-like, and accumulated (p53+) or undetected p53 (p53−). Given its lower costs this system has the potential for clinical applicability. Our results confirm relevant molecular alterations previously reported by TCGA and ACRG. We confirm EBV+ and MMR-D patients had the best prognosis and could be candidates for immunotherapy. Conversely, EMT-like displayed the poorest prognosis; our data suggest FGFR2 or KRAS could serve as potential actionable targets for these patients. Finally, we propose a low-cost step-by-step stratification system for GC patients. To the best of our knowledge, this is the first Latin American report on a molecular classification for GC. Pending further validation, this stratification system could be implemented into the routine clinic
📖 Papers frequently viewed together
6 Citations
16 Citations
33 Citations
#1Salvatore CoralloH-Index: 12
#2Giovanni FucàH-Index: 16
Last. Maria Di BartolomeoH-Index: 28
view all 20 authors...
BACKGROUND: Epstein-Barr virus (EBV)-positive gastric cancers (GCs) have been recently identified as a molecular subgroup showing excellent outcomes after surgery for early-stage disease and responsiveness to immune checkpoint inhibitors (ICIs) for metastatic stage. No data are available on the prevalence, clinical characteristics, and prognosis of this subgroup of GCs in the metastatic setting. MATERIALS AND METHODS: In this cohort study, we assessed the impact of EBV status in patients with me...
4 CitationsSource
#1Yohei Kubota (Juntendo University)H-Index: 1
#2Akihito KawazoeH-Index: 14
Last. Kohei ShitaraH-Index: 46
view all 15 authors...
Purpose: We evaluated the association between molecular subtypes of advanced gastric cancer (AGC) and the efficacy of standard chemotherapy or immune checkpoint inhibitors. Experimental Design: Patients with AGC who received systemic chemotherapy from October 2015 to July 2018 with available molecular features were analyzed. We investigated the efficacy of standard first- (fluoropyrimidine + platinum ± trastuzumab) and second-line (taxanes ± ramucirumab) chemotherapy, and subsequent anti-PD-1 th...
14 CitationsSource
#1Melanie A. Krook (OSU: Ohio State University)H-Index: 6
#2Alexandria M. Lenyo (OSU: Ohio State University)H-Index: 1
Last. Sameek Roychowdhury (OSU: Ohio State University)H-Index: 32
view all 18 authors...
The fibroblast growth factor receptor (FGFR) signaling pathway is aberrantly activated in approximately 15-20% of intrahepatic cholangiocarcinoma patients. Currently, several FGFR kinase inhibitors are being assessed in clinical trials for patients with FGFR-altered cholangiocarcinoma. Despite evidence of initial responses and disease control, virtually all patients eventually develop acquired resistance. Thus, there is a critical need for the development of innovative therapeutic strategies to ...
28 CitationsSource
#1Arash EtemadiH-Index: 35
#2Saeid SafiriH-Index: 41
Last. Reza MalekzadehH-Index: 127
view all 186 authors...
Summary Background Stomach cancer is a major health problem in many countries. Understanding the current burden of stomach cancer and the differential trends across various locations is essential for formulating effective preventive strategies. We report on the incidence, mortality, and disability-adjusted life-years (DALYs) due to stomach cancer in 195 countries and territories from 21 regions between 1990 and 2017. Methods Estimates from GBD 2017 were used to analyse the incidence, mortality, ...
88 CitationsSource
#1Dafna Bar-Sagi (NYU: New York University)H-Index: 92
#2Erik H. Knelson (Harvard University)H-Index: 10
Last. Lecia V. Sequist (Harvard University)H-Index: 96
view all 3 authors...
KRAS mutations are among the most prevalent tumor drivers, but targeting them pharmacologically has been challenging. Recent landmark studies have demonstrated promising clinical results of KRASG12C inhibition by using small molecules. Bar-Sagi, and Knelson and Sequist provide their distinct perspectives on this recent tour de force in targeting KRASG12C alterations.
22 CitationsSource
#1Shih-Chiang Huang (CGU: Chang Gung University)H-Index: 13
#2Kwai-Fong Ng (CGU: Chang Gung University)H-Index: 8
Last. Tse-Ching Chen (CGU: Chang Gung University)H-Index: 31
view all 8 authors...
: Limited studies investigated clinicopathological and prognostic significance of histologic and molecular subgroups of gastric cancer concurrently. We retrospectively enrolled 1,248 patients with gastric cancer who received radical gastrectomy with lymphadenectomy and classified these cases into the Epstein-Barr virus (EBV)-associated and microsatellite instability (MSI)-associated subtypes by EBV-encoded small RNA in situ hybridization and immunohistochemical stains for DNA mismatch repair pro...
23 CitationsSource
#1Marcus Fernando Kodama Pertille Ramos (USP: University of São Paulo)H-Index: 11
#2Marina Alessandra Pereira (USP: University of São Paulo)H-Index: 11
Last. Tiago Biachi de Castria (USP: University of São Paulo)H-Index: 5
view all 9 authors...
BACKGROUND: Gastric cancer (GC) has been defined in distinct molecular subtypes with different therapeutic implications. However, its clinical significance and prognosis regarding standard chemotherapy (CMT) remains unclear. This study aimed to analyze the impact of perioperative or adjuvant treatment among subtypes of GC. METHODS: We retrospectively evaluated all stage II/III patients with GC who underwent a curative gastrectomy. Based on immunohistochemistry and in situ hybridization technique...
8 CitationsSource
#1Ji Cheng (Union Hospital)H-Index: 1
#2Ming Cai (TJMC: Tongji Medical College)H-Index: 3
Last. Kaixiong Tao (TJMC: Tongji Medical College)H-Index: 3
view all 6 authors...
Background:Systemic therapy is the standard treatment against advanced gastric cancer. Fluoropyrimidine plus platinum doublet has been recommended as the preferred first-line strategy. However, the...
6 CitationsSource
#1Shamaine Wei Ting Ho (NUS: National University of Singapore)H-Index: 4
#2Patrick TanH-Index: 90
Last. Patrick TanH-Index: 1
view all 2 authors...
Gastric cancer (GC) remains the fifth most prevalent cancer worldwide and the third leading cause of global cancer mortality. Comprehensive ‐omic studies have unveiled a heterogeneous GC landscape, with considerable molecular diversity both between and within tumors. Given the complex nature of GC, a long‐sought goal includes effective identification of distinct patient subsets with prognostic and/or predictive outcomes to enable tailoring of specific treatments (“precision oncology”). In this r...
24 CitationsSource
#1Chang Hwan Yoon (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 40
#2Jacob Till (UPenn: University of Pennsylvania)H-Index: 9
Last. Sam S. Yoon (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 58
view all 8 authors...
Our previous work showed that in a mouse model of gastric adenocarcinoma (GA) with loss of p53 and Cdh1 that adding oncogenic Kras (a.k.a. Tcon mice) accelerates tumorigenesis and metastasis. Here we sought to examine KRAS activation in epithelial-to-mesenchymal transition (EMT) and generation of cancer stem-like cells (CSCs). Transduction of nontransformed HFE-145 gastric epithelial cells with oncogenic KRASG12V significantly decreased expression of the epithelial marker E-cadherin, increased e...
13 CitationsSource
Cited By5
#2Ronny NienholdH-Index: 11
Last. Gieri CathomasH-Index: 38
view all 7 authors...
Gastric adenocarcinoma (GAC) is a heterogeneous disease and at least two major studies have recently provided a molecular classification for this tumor: The Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ARCG). Both classifications quote four molecular subtypes, but these subtypes only partially overlap. In addition, the classifications are based on complex and cost-intensive technologies, which are hardly feasible for everyday practice. Therefore, simplified approaches using im...
#2Isabel Arranz-Salas (UMA: University of Málaga)
Last. D. Bermúdez (UMA: University of Málaga)H-Index: 3
view all 10 authors...
Gastric cancer (GC) is one of the leading causes of cancer-related death. The combination of new molecular classifications with clinicopathological data could contribute to the individualization of patients and to the development of new therapeutic strategies. We examined the various associations in two molecular types of GC: HER2-positive (human epidermal growth factor receptor 2) and microsatellite instability (MSI), assessing their influence on treatment and prognosis. A retrospective study o...
#1José Garcia-Pelaez (University of Porto)H-Index: 1
#2Rita Barbosa-Matos (Institute of Molecular Pathology and Immunology of the University of Porto)
Last. Carla Oliveira (Institute of Molecular Pathology and Immunology of the University of Porto)H-Index: 62
view all 5 authors...
Gastric cancer (GC) pathogenesis is complex and heterogeneous, reflecting morphological, molecular, and genetic diversity. Diffuse gastric cancer (DGC) and intestinal gastric cancer (IGC) are the major histological types. GC may be sporadic or hereditary; sporadic GC is related to environmental and genetic low-risk factors and hereditary GC is caused by inherited high-risk mutations, so far identified only for the diffuse histotype. DGC phenotypic heterogeneity challenges the current understandi...
#1Fahad Albalawi (UPM: Universiti Putra Malaysia)H-Index: 1
#1Fahad Ma Albalawi (King Fahad Specialist Hospital)H-Index: 1
Last. Mas Jaffri MasarudinH-Index: 13
view all 4 authors...
The emergence of nanotechnology as a key enabling technology over the past years has opened avenues for new and innovative applications in nanomedicine. From the business aspect, the nanomedicine market was estimated to worth USD 293.1 billion by 2022 with a perception of market growth to USD 350.8 billion in 2025. Despite these opportunities, the underlying challenges for the future of engineered nanomaterials (ENMs) in nanomedicine research became a significant obstacle in bringing ENMs into c...
1 CitationsSource
#1Yanyan Chen (ZJU: Zhejiang University)H-Index: 4
#2Quan Zhou (ZJU: Zhejiang University)H-Index: 1
Last. Lisong Teng (ZJU: Zhejiang University)H-Index: 26
view all 9 authors...
Gastric cancer (GC) is a leading cause of worldwide cancer-related death. Being a highly heterogeneous disease, the current treatment of GC has been suboptimal due to the lack of subtype-dependent therapies. Peritoneal dissemination (PD) is a common pattern of GC metastasis associated with poor prognosis. Therefore, it is urgently necessary to identify patients at high risk of PD. PD is found to be associated with Lauren diffuse type GC. Molecular profiling of GC, especially diffuse type GC, has...
5 CitationsSource